The Oncotype MAP™ Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. Using next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the test identifies actionable genomic alterations within 3-5 business days and with small tissue sample sizes.1 The test guides timely discussions and decisions, while helping physicians understand a patient’s tumor profile to recommend targeted therapies or clinical trials.


 

1Internal Data on File. Exact Sciences Corporation. Madison, WI. Turnaround time based on qualified sample receipt.